Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Portfolio Pulse from
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced that the CHMP has given a positive opinion for acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), recommending its marketing authorization in the EU. This follows successful Phase 3 trials showing cardiovascular benefits.
December 13, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BridgeBio Pharma's acoramidis received a positive CHMP opinion for treating ATTR-CM, recommending EU marketing authorization. This could enhance BBIO's market presence and revenue potential.
The positive CHMP opinion is a significant regulatory milestone for BridgeBio, potentially leading to EU market entry for acoramidis. This can increase BBIO's revenue and market presence, positively impacting its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100